Michael Dibernardo, MD
Family Medicine · Kansas City, MONPI 1235109851
Payments from drug & device makers
Across 191 payments — averaging $13.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$765
- Pfizer$326
- Abbott$164
- Boehringer Ingelheim$163
- Novo Nordisk$154
- AstraZeneca$144
- plus $943 from 24 others
What the payments were for
- Food & beverage$2,57197%
- Education$391%
- Other$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $765 |
| Pfizer | 30 | $326 |
| Abbott | 8 | $164 |
| Boehringer Ingelheim | 12 | $163 |
| Novo Nordisk | 11 | $154 |
| AstraZeneca | 11 | $144 |
| Lilly USA, LLC | 10 | $135 |
| Amgen(2 entities) | 9 | $130 |
| Johnson & Johnson | 6 | $77 |
| Supernus Pharmaceuticals, Inc. | 4 | $63 |
| Merck | 4 | $56 |
| Boston Scientific | 1 | $44 |
| Astellas Pharma US Inc | 3 | $44 |
| Daiichi Sankyo Inc. | 3 | $40 |
| GSK | 3 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Globus Medical | 1 | $29 |
| Eisai Inc. | 2 | $27 |
| Novartis | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Bayer | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Optinose US, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$2,659 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 250 | $287,937 |
| JardianceEmpagliflozin | 197 | $166,125 |
| EliquisApixaban | 124 | $113,796 |
| MounjaroTirzepatide | 79 | $90,469 |
| TrulicityDulaglutide | 53 | $55,705 |
| FarxigaDapagliflozin Propanediol | 35 | $48,626 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 107 | $34,115 |
| JanuviaSitagliptin Phosphate | 25 | $28,888 |
| RybelsusSemaglutide | 21 | $27,833 |
| MyrbetriqMirabegron | 72 | $21,686 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $15,894 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $13,951 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $13,109 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $12,690 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 49 | $10,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $154 | $315,770271 claims |
| Boehringer IngelheimJardiance | $163 | $166,125197 claims |
| PfizerEliquis, Abrysvo, Paxlovid | $326 | $153,341267 claims |
| Lilly USA, LLCMounjaro, Trulicity | $135 | $146,174132 claims |
| AstraZenecaFarxiga, Symbicort | $144 | $54,53852 claims |
| MerckJanuvia, Janumet | $56 | $44,78141 claims |
| GSKShingrix, Arnuity Ellipta, Anoro Ellipta | $40 | $23,13887 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $21,68672 claims |
| Johnson & JohnsonXarelto | $77 | $7,25613 claims |
| AbbVieSynthroid | $765 | $7,05687 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Kansas City
- Scott KuennenKansas City$2.2M
- Blair ThedingerKansas City$1.3M
- Heather JordanKansas City$70K
- Jon MattsonKansas City$53K
- Meredith LevineKansas City$26K
- Cindy ChangKansas City$22K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.